November 04, 2020

Additional high-speed production lines at its UK and Puerto Rico facilities

FAREHAM, Hampshire, November 4th, 2020—CooperVision’s flagship one-day silicone hydrogel contact lens franchise, MyDay®, has benefitted from significant investment by the company in its manufacturing capability. The move has increased production capacity to meet the increase in demand, as well as projected growth in the coming years.  

The company cited the ongoing shift to one-day lenses, the preference for highly breathable silicone hydrogel material technologies and the demand for its MyDay® sphere and toric products as factors behind the move.

The investment represents the company’s most aggressive manufacturing expansion plan within the last ten years. It means that by 2021, manufacturing capacity of the MyDay® brand will have increased more than 300% since 2018 through additional high-speed production lines at both its UK and Puerto Rico facilities. Alongside this, the company has introduced a flexible stock management process with dual sourcing, which is designed to ensure reliable supply.

Rob Healey, Portfolio Director EMEA, commented: “MyDay® is CooperVision’s most breathable and softest one-day silicone hydrogel contact lens and is designed to offer eye care professionals and wearers a high-performance option for when performance matters.” He added; “We’ve seen demand for MyDay® and MyDay® toric grow significantly with the brand now prescribed to millions of wearers worldwide, and this substantial investment at our UK and Puerto Rico sites means we have built-in capacity for many years ahead.”

MyDay® is available in sphere and toric modalities for patients with myopia, hyperopia and astigmatism.

For more information, visit

# # #

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit